ABSTRACT
Alkaptonuria (AKU) is an ultra-rare genetic disease caused by a deficient activity of the enzyme homogentisate 1,2-dioxygenase (HGD) leading to the accumulation of homogentisic acid (HGA) on connective tissues. Even though AKU is a multi-systemic disease, osteoarticular cartilage is the most affected system and the most damaged tissue by the disease. In chondrocytes, HGA causes oxidative stress dysfunctions, which induce a series of not fully characterized cellular responses. In this study, we used a human chondrocytic cell line as an AKU model to evaluate, for the first time, the effect of HGA on autophagy, the main homeostasis system in articular cartilage. Cells responded timely to HGA treatment with an increase in autophagy as a mechanism of protection. In a chronic state, HGA-induced oxidative stress decreased autophagy, and chondrocytes, unable to restore balance, activated the chondroptosis pathway. This decrease in autophagy also correlated with the accumulation of ochronotic pigment, a hallmark of AKU. Our data suggest new perspectives for understanding AKU and a mechanistic model that rationalizes the damaging role of HGA.
Subject(s)
Alkaptonuria/prevention & control , Autophagy/drug effects , Biomarkers/metabolism , Homogentisate 1,2-Dioxygenase/metabolism , Homogentisic Acid/metabolism , Alkaptonuria/metabolism , Apoptosis/drug effects , Cartilage, Articular/drug effects , Cell Line , Chondrocytes/cytology , Homogentisic Acid/pharmacology , Humans , Ochronosis/metabolism , Oxidative Stress/drug effects , Signal TransductionABSTRACT
Alkaptonuria (AKU), a rare genetic disorder, is characterized by the accumulation of homogentisic acid (HGA) in organs due to a deficiency in functional levels of the enzyme homogentisate 1,2-dioxygenase (HGD), required for the breakdown of HGA, because of mutations in the HGD gene. Over time, HGA accumulation causes the formation of the ochronotic pigment, a dark deposit that leads to tissue degeneration and organ malfunction. Such behaviour can be observed also in vitro for HGA solutions or HGA-containing biofluids (e.g. urine from AKU patients) upon alkalinisation, although a comparison at the molecular level between the laboratory and the physiological conditions is lacking. Indeed, independently from the conditions, such process is usually explained with the formation of 1,4-benzoquinone acetic acid (BQA) as the product of HGA chemical oxidation, mostly based on structural similarity between HGA and hydroquinone that is known to be oxidized to the corresponding para-benzoquinone. To test such correlation, a comprehensive, comparative investigation on HGA and BQA chemical behaviours was carried out by a combined approach of spectroscopic techniques (UV spectrometry, Nuclear Magnetic Resonance, Electron Paramagnetic Resonance, Dynamic Light Scattering) under acid/base titration both in solution and in biofluids. New insights on the process leading from HGA to ochronotic pigment have been obtained, spotting out the central role of radical species as intermediates not reported so far. Such evidence opens the way for molecular investigation of HGA fate in cells and tissue aiming to find new targets for Alkaptonuria therapy.
Subject(s)
Acetates/urine , Alkaptonuria/urine , Benzoquinones/urine , Homogentisate 1,2-Dioxygenase/metabolism , Homogentisic Acid/urine , Ochronosis/metabolism , Ochronosis/urine , Adult , Aged , Alkaptonuria/enzymology , Alkaptonuria/genetics , Case-Control Studies , Dynamic Light Scattering , Electron Spin Resonance Spectroscopy , Female , Homogentisate 1,2-Dioxygenase/genetics , Humans , Magnetic Resonance Spectroscopy , Male , Middle Aged , Mutation , Ochronosis/enzymology , Ochronosis/genetics , Oxidation-Reduction , Spectrophotometry, Ultraviolet , UrinalysisABSTRACT
A 52-year-old men suffered from osteoarthritis of the knee. During knee replacement surgery, the remaining cartilage appeared black. This discoloration and early degeneration of the cartilage is characteristic for the metabolic disorder alkaptonuria in which homogentisic acid accumulates in the body.
Subject(s)
Alkaptonuria , Arthroplasty, Replacement, Knee , Cartilage/pathology , Knee Joint/pathology , Knee/pathology , Ochronosis , Alkaptonuria/complications , Alkaptonuria/metabolism , Alkaptonuria/surgery , Cartilage/metabolism , Cartilage/surgery , Color , Homogentisic Acid/metabolism , Humans , Incidental Findings , Knee/surgery , Knee Joint/metabolism , Knee Joint/surgery , Male , Middle Aged , Ochronosis/etiology , Ochronosis/metabolism , Ochronosis/surgery , Osteoarthritis/complications , Osteoarthritis/surgeryABSTRACT
A large alkaptonuria (AKU) cohort was studied to better characterize the poorly understood spondyloarthropathy of rare disease AKU. Eighty-seven patients attended the National Alkaptonuria Centre (NAC) between 2007 and 2020. Seven only attended once. Fifty-seven attended more than once and received nitisinone 2 mg daily. Twenty-three attended at least twice without receiving nitisinone. Assessments included questionnaire analysis, 18F Positron emission tomography computerised tomography (PETCT), as well as photographs of ochronotic pigment in eyes and ears at baseline when 2 mg nitisinone was commenced and yearly thereafter. Blood and urine samples were collected for chemical measurement. The prevalence of ochronosis, as well as pain, PETCT and combined pain and PETCT scores, was greatly increased at 90.5%, 85.7%, 100%, and 100%, respectively. Joint pain scores were greatest in proximal joints in upper and lower limbs. PETCT joint scores were higher in proximal joints in upper limb but higher in distal joints in the lower limb. Spine pain scores were highest in lumbar, followed by cervical, thoracic, and cervical regions at 77.4%, 59.5%, 46.4%, and 25%, respectively. PETCT spine scores were highest in thoracic followed by lumbar, cervical, and sacroiliac regions at 74.4%, 70.7%, 64.6%, and 47.8% respectively; ochronosis associated closely with spondyloarthropathy scores (R = .65; P < .0001). Nitisinone reversed ochronosis significantly, with a similar pattern of decreased joint and spine disease. Spondyloarthropathy is a highly prevalent feature in this NAC cohort. Ochronosis appears to be associated with spondyloarthropathy. Nitisinone decreases ochronosis and had a similar nonsignificant effect pattern on spondyloarthropathy.
Subject(s)
Alkaptonuria/drug therapy , Cyclohexanones/administration & dosage , Homogentisic Acid/metabolism , Joints/pathology , Nitrobenzoates/administration & dosage , Ochronosis/drug therapy , Spine/pathology , Aged , Alkaptonuria/metabolism , Cohort Studies , Female , Humans , Joints/diagnostic imaging , Linear Models , Male , Middle Aged , Ochronosis/metabolism , Phenotype , Positron Emission Tomography Computed Tomography , Severity of Illness Index , Spine/diagnostic imaging , United KingdomABSTRACT
Alkaptonuria (AKU) is a rare disease correlated with deficiency of the enzyme homogentisate 1,2 dioxygenase, which causes homogentisic acid (HGA) accumulation. HGA is subjected to oxidation/polymerization reactions, leading to the production of a peculiar melanin-like pigmentation (ochronosis) after chronic inflammation, which is considered as a triggering event for the generation of oxidative stress. Clinical manifestations of AKU are urine darkening, sclera pigmentation, early severe osteoarthropathy, and cardiovascular and renal complication. Despite major clinical manifestations of AKU being observed in the bones and skeleton, the molecular and functional parameters are so far unknown in AKU. In the present study, we used human osteoblasts supplemented with HGA as a AKU cellular model. We observed marked oxidative stress, and for the first time, we were able to correlate HGA deposition with an impairment in the Wnt/ß-catenin signaling pathway, opening a range of possible therapeutic strategies for a disease still lacking a known cure.
Subject(s)
Homogentisic Acid/pharmacology , Osteoblasts/drug effects , Oxidative Stress/drug effects , Wnt Signaling Pathway/drug effects , beta Catenin/metabolism , Alkaptonuria/metabolism , Bone and Bones/drug effects , Bone and Bones/metabolism , Cells, Cultured , Humans , Inflammation/metabolism , Melanins/metabolism , Ochronosis/metabolism , Osteoblasts/metabolism , Oxidation-Reduction/drug effects , Pigmentation/drug effects , Signal Transduction/drug effectsABSTRACT
QUESTION: Does Nitisinone prevent the clinical progression of the Alkaptonuria? FINDINGS: In this observational study on 39 patients, 2â¯mg of daily nitisinone inhibited ochronosis and significantly slowed the progression of AKU over a three-year period. MEANING: Nitisinone is a beneficial therapy in Alkaptonuria. BACKGROUND: Nitisinone decreases homogentisic acid (HGA), but has not been shown to modify progression of Alkaptonuria (AKU). METHODS: Thirty-nine AKU patients attended the National AKU Centre (NAC) in Liverpool for assessments and treatment. Nitisinone was commenced at V1 or baseline. Thirty nine, 34 and 22 AKU patients completed 1, 2 and 3â¯years of monitoring respectively (V2, V3 and V4) in the VAR group. Seventeen patients also attended a pre-baseline visit (V0) in the VAR group. Within the 39 patients, a subgroup of the same ten patients attended V0, V1, V2, V3 and V4 visits constituting the SAME Group. Severity of AKU was assessed by calculation of the AKU Severity Score Index (AKUSSI) allowing comparison between the pre-nitisinone and the nitisinone treatment phases. RESULTS: The ALL (sum of clinical, joint and spine AKUSSI features) AKUSSI rate of change of scores/patient/month, in the SAME group, was significantly lower at two (0.32⯱â¯0.19) and three (0.15⯱â¯0.13) years post-nitisinone when compared to pre-nitisinone (0.65⯱â¯0.15) (pâ¯<â¯.01 for both comparisons). Similarly, the ALL AKUSSI rate of change of scores/patient/month, in the VAR group, was significantly lower at one (0.16⯱â¯0.08) and three (0.19⯱â¯0.06) years post-nitisinone when compared to pre-nitisinone (0.59⯱â¯0.13) (pâ¯<â¯.01 for both comparisons). Combined ear and ocular ochronosis rate of change of scores/patient/month was significantly lower at one, two and three year's post-nitisinone in both VAR and SAME groups compared with pre-nitisinone (pâ¯<â¯.05). CONCLUSION: This is the first indication that a 2â¯mg dose of nitisinone slows down the clinical progression of AKU. Combined ocular and ear ochronosis progression was arrested by nitisinone.
Subject(s)
Alkaptonuria/drug therapy , Cyclohexanones/administration & dosage , Nitrobenzoates/administration & dosage , Ochronosis/drug therapy , 4-Hydroxyphenylpyruvate Dioxygenase/metabolism , Alkaptonuria/epidemiology , Alkaptonuria/metabolism , Alkaptonuria/pathology , Disease Progression , Female , Homogentisic Acid/metabolism , Humans , Male , Middle Aged , Ochronosis/epidemiology , Ochronosis/metabolism , Ochronosis/pathology , United KingdomABSTRACT
BACKGROUND: Alkaptonuria (AKU) is an ultra-rare inborn error of metabolism characterized by homogentisic acid (HGA) accumulation due to a deficient activity of the homogentisate 1.2-dioxygenase (HGD) enzyme. This leads to the production of dark pigments that are deposited onto connective tissues, a condition named 'ochronosis' and whose mechanisms are not completely clear. Recently, the potential role of hitherto unidentified proteins in the ochronotic process was hypothesized, and the presence of Serum Amyloid A (SAA) in alkaptonuric tissues was reported, allowing the classification of AKU as a novel secondary amyloidosis. METHODS: Gel electrophoresis, Western Blot, Congo Red-based assays and electron microscopy were used to investigate the effects of HGA on the aggregation and fibrillation propensity of amyloidogenic proteins and peptides [Aß(1-42), transthyretin, atrial natriuretic peptide, α-synuclein and SAA]. LC/MS and in silico analyses were undertaken to identify possible binding sites for HGA (or its oxidative metabolite, a benzoquinone acetate or BQA) in SAA. RESULTS: We found that HGA might act as an amyloid aggregation enhancer in vitro for all the tested proteins and peptides in a time- and dose- dependent fashion, and identified a small crevice at the interface between two HGD subunits as a candidate binding site for HGA/BQA. CONCLUSIONS: HGA might be an important amyloid co- component playing significant roles in AKU amyloidosis. GENERAL SIGNIFICANCE: Our results provide a possible explanation for the clinically verified onset of amyloidotic processes in AKU and might lay the basis to setup proper pharmacological approaches to alkaptonuric ochronosis, which are still lacking.
Subject(s)
Amyloidogenic Proteins/metabolism , Homogentisic Acid/pharmacology , Protein Aggregation, Pathological/chemically induced , Alkaptonuria/metabolism , Amyloid beta-Peptides/metabolism , Amyloidosis/metabolism , Atrial Natriuretic Factor/metabolism , Binding Sites/drug effects , Connective Tissue/drug effects , Connective Tissue/metabolism , Homogentisate 1,2-Dioxygenase/metabolism , Humans , Ochronosis/metabolism , Oxidation-Reduction/drug effects , Prealbumin/metabolism , Serum Amyloid A Protein/metabolism , alpha-Synuclein/metabolismABSTRACT
OBJECTIVE: Alkaptonuria (AKU) is a rare autosomal recessive disease resulting from a single enzyme deficiency in tyrosine metabolism. As a result, homogentisic acid cannot be metabolized, causing systemic increases. Over time, homogentisic acid polymerizes and deposits in collagenous tissues, leading to ochronosis. Typically, this occurs in joint cartilages, leading to an early onset, rapidly progressing osteoarthropathy. The aim of this study was to examine tissue turnover in cartilage affected by ochronosis and its role in disease initiation and progression. METHODS: With informed patient consent, hip and knee cartilages were obtained at surgery for arthropathy due to AKU (n = 6; 2 knees/4 hips) and OA (n = 12; 5 knees/7 hips); healthy non-arthritic (non-OA n = 6; 1 knee/5 hips) cartilages were obtained as waste from trauma surgery. We measured cartilage concentrations (normalized to dry weight) of racemized aspartate, GAG, COMP and deamidated COMP (D-COMP). Unpaired AKU, OA and non-OA samples were compared by non-parametric Mann-Whitney U test. RESULTS: Despite more extractable total protein being obtained from AKU cartilage than from OA or non-OA cartilage, there was significantly less extractable GAG, COMP and D-COMP in AKU samples compared with OA and non-OA comparators. Racemized Asx (aspartate and asparagine) was significantly enriched in AKU cartilage compared with in OA cartilage. CONCLUSIONS: These novel data represent the first examination of cartilage matrix components in a sample of patients with AKU, representing almost 10% of the known UK alkaptonuric population. Compared with OA and non-OA, AKU cartilage demonstrates a very low turnover state and has low levels of extractable matrix proteins.
Subject(s)
Aging/metabolism , Alkaptonuria/metabolism , Cartilage, Articular/metabolism , Joint Diseases/metabolism , Ochronosis/metabolism , Adult , Aged , Aged, 80 and over , Aspartic Acid/metabolism , Biomarkers/metabolism , Cartilage Oligomeric Matrix Protein/metabolism , Case-Control Studies , Female , Glycosaminoglycans/metabolism , Hip Joint , Humans , Knee Joint , Male , Middle Aged , Osteoarthritis, Hip/metabolism , Osteoarthritis, Knee/metabolism , Young AdultABSTRACT
Alkaptonuria is a rare autosomal recessive condition resulting from inability to breakdown homogentisic acid (HGA), an intermediate in tyrosine degradation. The condition has a triad of clinical features, the most damaging of which is ochronotic osteoarthropathy. HGA is elevated from birth, but pigmentation takes many years. We hypothesise that interleukins play a role in initiation and progression of ochronotic osteoarthropathy. C20/A4 cells were cultured and maintained in 9-cm petri dishes containing either HGA at 0.33 mM, a single interleukin (IL-1ß, IL-6 or IL-10) at 1 ng/ml or a combination of HGA and a single interleukin. Statistical analysis of pigment deposits and cell viability was performed using analysis of variance with Newman-Keuls post-test. All cultures containing HGA showed a significant increase in pigment deposition compared to control and IL cultures alone. The cultures containing HGA and IL-6 showed a significant increase in pigment deposits compared to HGA alone. The cell viability counts across all cultures on day 10 demonstrated a significant decrease in cultures containing HGA compared to those which did not. There was no significant difference between cultures containing just HGA or those combined with an interleukin. This work demonstrates a role for cytokines present in the joint(s) in the pigmentation process, particularly IL-6, and that the presence of HGA in joint tissues appears more detrimental to chondrocytes than the presence of any of the interleukins found in response to joint injury, trauma and osteoarthritis (OA). This further supports the evidence that the arthropathy in alkaptonuria is much more severe and rapidly progressing.
Subject(s)
Chondrocytes/metabolism , Interleukin-10/metabolism , Interleukin-6/metabolism , Ochronosis/metabolism , Pigmentation , Alkaptonuria/metabolism , Cell Line , Homogentisic Acid/adverse effects , Humans , Ochronosis/chemically induced , Osteoarthritis/metabolismSubject(s)
Aortic Valve Stenosis/surgery , Aortic Valve/surgery , Homogentisic Acid/metabolism , Ochronosis/complications , Pigments, Biological/metabolism , Aortic Valve/metabolism , Aortic Valve Stenosis/diagnosis , Aortic Valve Stenosis/etiology , Aortic Valve Stenosis/metabolism , Biopsy , Heart Valve Prosthesis Implantation , Humans , Male , Middle Aged , Ochronosis/diagnosis , Ochronosis/metabolism , Sclera/metabolism , Scleral Diseases/etiology , Scleral Diseases/metabolismABSTRACT
Alkaptonuria (AKU) is an ultra-rare inborn error of metabolism developed from the lack of homogentisic acid oxidase activity, causing homogentisic acid (HGA) accumulation that produces an HGA-melanin ochronotic pigment, of hitherto unknown composition. Besides the accumulation of HGA, the potential role and presence of unidentified proteins has been hypothesized as additional causal factors involved in ochronotic pigment deposition. Evidence has been provided on the presence of serum amyloid A (SAA) in several AKU tissues, which allowed classifying AKU as a novel secondary amyloidosis. In this paper, we will briefly review all direct and indirect lines of evidence related to the presence of amyloidosis in AKU. We also report the first data on abnormal SAA serum levels in a cohort of AKU patients.
Subject(s)
Alkaptonuria/complications , Amyloidosis/etiology , Alkaptonuria/metabolism , Alkaptonuria/pathology , Amyloidosis/metabolism , Amyloidosis/pathology , Cartilage/metabolism , Cartilage/pathology , Humans , Inflammation/complications , Inflammation/metabolism , Inflammation/pathology , Ochronosis/complications , Ochronosis/metabolism , Ochronosis/pathology , Oxidative Stress/physiology , Staining and Labeling/methodsABSTRACT
Alkaptonuria is an ultra-rare autosomal recessive disease developed from the lack of homogentisate 1,2-dioxygenase (HGD) activity, causing an accumulation in connective tissues of homogentisic acid (HGA) and its oxidized derivatives in polymerized form. The deposition of ochronotic pigment has been so far attributed to homogentisic acid produced by the liver, circulating in the blood, and accumulating locally. In the present paper, we report the expression of HGD in the brain. Mouse and human brain tissues were positively tested for HGD gene expression by western blotting. Furthermore, HGD expression was confirmed in human neuronal cells that also revealed the presence of six HGD molecular species. Moreover, once cultured in HGA excess, human neuronal cells produced ochronotic pigment and amyloid. Our findings indicate that alkaptonuric brain cells produce the ochronotic pigment in loco and this may contribute to induction of neurological complications.
Subject(s)
Alkaptonuria/metabolism , Brain/metabolism , Homogentisate 1,2-Dioxygenase/metabolism , Alkaptonuria/pathology , Animals , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/pathology , Blotting, Western , Brain/pathology , Cell Line, Tumor , Homogentisic Acid/metabolism , Humans , Male , Mice , Ochronosis/metabolism , Ochronosis/pathologyABSTRACT
Alkaptonuria is a rare inborn error of metabolism, identified over a century ago. But its basic pathomechanism (i.e. ochronosis) is still not completely explained. Though clinical onset of osteoarthropathy and complications from other organs (including: heart and blood vessels, skin, eyes, kidneys) occurs at adult age, the symptoms are progressive, cause severe pains and significantly limit everyday life of the patients. Until now no effective therapeutic methods have been known in alkaptonuria. Recently, thanks to an initiative of the international patient organization for alkaptonuria, a hope for a potential treatment availability, appears. So, alkaptonuria is an example of a role of multidysciplinary care, cooperation and ongoing progress in the area of rare diseases.
Subject(s)
Alkaptonuria/complications , Aortic Valve Stenosis/etiology , Ochronosis/etiology , Alkaptonuria/metabolism , Aortic Valve Stenosis/surgery , Heart Valve Prosthesis Implantation , Humans , Ochronosis/metabolism , Ochronosis/surgeryABSTRACT
BACKGROUND: Alkaptonuria, a rare autosomal recessive metabolic disorder caused by deficiency in homogentisate 1,2-dioxygenase activity, leads to accumulation of oxidised homogentisic acid in cartilage and collagenous structures present in all organs and tissues, especially joints and heart, causing a pigmentation called ochronosis. A secondary amyloidosis is associated with AKU. Here we report a study of an aortic valve from an AKU patient. RESULTS: Congo Red birefringence, Th-T fluorescence, and biochemical assays demonstrated the presence of SAA-amyloid deposits in AKU stenotic aortic valve. Light and electron microscopy assessed the colocalization of ochronotic pigment and SAA-amyloid, the presence of calcified areas in the valve. Immunofluorescence detected lipid peroxidation of the tissue and lymphocyte/macrophage infiltration causing inflammation. High SAA plasma levels and proinflammatory cytokines levels comparable to those from rheumatoid arthritis patients were found in AKU patient. CONCLUSIONS: SAA-amyloidosis was present in the aortic valve from an AKU patient and colocalized with ochronotic pigment as well as with tissue calcification, lipid oxidation, macrophages infiltration, cell death, and tissue degeneration. A local HGD expression in human cardiac tissue has also been ascertained suggesting a consequent local production of ochronotic pigment in AKU heart.
Subject(s)
Alkaptonuria/immunology , Alkaptonuria/metabolism , Amyloidosis/physiopathology , Inflammation/physiopathology , Oxidative Stress , Aged , Aortic Valve/metabolism , Arthritis, Rheumatoid/blood , Female , Humans , Lipid Peroxidation , Lymphocytes/cytology , Macrophages/cytology , Myocardium/metabolism , Ochronosis/metabolism , Serum Amyloid A Protein/metabolismABSTRACT
Alkaptonuria is a rare inherited disorder of tyrosine metabolism, which results in deposition of homogentisic acid in the connective tissues. The accumulation of homogentisic acid in connective tissue causes the syndrome known as ochronosis, which is typically manifested by skin pigmentation, degenerative arthropathy and discolouration of urine. Cardiovascular involvement is a much less common complication of alkaptonuria but poses a greater risk to the patient's health. We present the case of a 65 year-old man with aortic stenosis and a previous diagnosis of alkaptonuria who underwent successful aortic valve replacement with a mechanical prosthesis.
Subject(s)
Alkaptonuria , Aortic Valve Stenosis , Heart Valve Prosthesis , Aged , Alkaptonuria/complications , Alkaptonuria/metabolism , Alkaptonuria/surgery , Aortic Valve Stenosis/complications , Aortic Valve Stenosis/metabolism , Aortic Valve Stenosis/surgery , Homogentisic Acid/metabolism , Humans , Male , Ochronosis/complications , Ochronosis/metabolism , Ochronosis/surgery , Skin Pigmentation , SyndromeABSTRACT
Alkaptonuria (AKU) is a rare genetic disease associated with the accumulation of homogentisic acid (HGA) and its oxidized/polymerized products which leads to the deposition of melanin-like pigments (ochronosis) in connective tissues. Although numerous case reports have described ochronosis in joints, little is known on the molecular mechanisms leading to such a phenomenon. For this reason, we characterized biochemically chondrocytes isolated from the ochronotic cartilage of AKU patients. Based on the macroscopic appearance of the ochronotic cartilage, two sub-populations were identified: cells coming from the black portion of the cartilage were referred to as "black" AKU chondrocytes, while those coming from the white portion were referred to as "white" AKU chondrocytes. Notably, both AKU chondrocytic types were characterized by increased apoptosis, NO release, and levels of pro-inflammatory cytokines. Transmission electron microscopy also revealed that intracellular ochronotic pigment deposition was common to both "white" and "black" AKU cells. We then undertook a proteomic and redox-proteomic analysis of AKU chondrocytes which revealed profound alterations in the levels of proteins involved in cell defence, protein folding, and cell organization. An increased post-translational oxidation of proteins, which also involved high molecular weight protein aggregates, was found to be particularly relevant in "black" AKU chondrocytes.
Subject(s)
Alkaptonuria/metabolism , Cartilage/metabolism , Cartilage/pathology , Chondrocytes/metabolism , Cytokines/metabolism , Nitric Oxide/metabolism , Ochronosis/genetics , Aged , Alkaptonuria/genetics , Alkaptonuria/pathology , Apoptosis/genetics , Cell Proliferation , Chondrocytes/pathology , Cytokines/genetics , Female , Gene Expression Regulation , Humans , Male , Microscopy, Electron, Transmission , Middle Aged , Ochronosis/metabolism , Ochronosis/pathology , Oxidation-Reduction , Pigmentation/genetics , Proteome/genetics , Proteome/metabolismSubject(s)
Alkaptonuria/diagnosis , Low Back Pain/diagnosis , Magnetic Resonance Imaging/methods , Alkaptonuria/complications , Alkaptonuria/urine , Diagnosis, Differential , Gas Chromatography-Mass Spectrometry , Homogentisic Acid/analysis , Homogentisic Acid/metabolism , Humans , Intervertebral Disc/pathology , Low Back Pain/etiology , Low Back Pain/urine , Male , Middle Aged , Ochronosis/etiology , Ochronosis/metabolism , Ochronosis/pathology , Spondylarthropathies/diagnosisABSTRACT
Alkaptonuria (AKU) results from defective homogentisate1,2-dioxygenase (HGD), causing degenerative arthropathy. The deposition of ochronotic pigment in joints is so far attributed to homogentisic acid produced by the liver, circulating in the blood and accumulating locally. Human normal and AKU osteoarticular cells were tested for HGD gene expression by RT-PCR, mono- and 2D-Western blotting. HGD gene expression was revealed in chondrocytes, synoviocytes, osteoblasts. Furthermore, HGD expression was confirmed by Western blotting, that also revealed the presence of five enzymatic molecular species. Our findings indicate that AKU osteoarticular cells produce the ochronotic pigment in loco and this may strongly contribute to induction of ochronotic arthropathy.
Subject(s)
Alkaptonuria/metabolism , Homogentisate 1,2-Dioxygenase/metabolism , Ochronosis/metabolism , Synovial Membrane/metabolism , Aged , Alkaptonuria/genetics , Cells, Cultured , Chondrocytes/metabolism , Gene Expression/genetics , Homogentisate 1,2-Dioxygenase/genetics , Humans , Middle Aged , Osteoblasts/cytology , Osteoblasts/metabolism , Synovial Membrane/cytologyABSTRACT
OBJECTIVE: Alkaptonuria is a genetic disorder of tyrosine metabolism, resulting in elevated circulating concentrations of homogentisic acid. Homogentisic acid is deposited as a polymer, termed ochronotic pigment, in collagenous tissues, especially cartilages of weight-bearing joints, leading to a severe osteoarthropathy. We undertook this study to investigate the initiation and progression of ochronosis from the earliest detection of pigment through complete joint failure. METHODS: Nine joint samples with varying severities of ochronosis were obtained from alkaptonuria patients undergoing surgery and compared to joint samples obtained from osteoarthritis (OA) patients. Samples were analyzed by light and fluorescence microscopy, 3-dimensional scanning electron microscopy (SEM), and the quantitative backscattered electron mode of SEM. Cartilage samples were mechanically tested by compression to determine Young's modulus of pigmented, nonpigmented, and OA cartilage samples. RESULTS: In alkaptonuria samples with the least advanced ochronosis, pigment was observed intracellularly and in the territorial matrix of individual chondrocytes at the boundary of the subchondral bone and calcified cartilage. In more advanced ochronosis, pigmentation was widespread throughout the hyaline cartilage in either granular composition or as blanket pigmentation in which there is complete and homogenous pigmentation of cartilage matrix. Once hyaline cartilage was extensively pigmented, there was aggressive osteoclastic resorption of the subchondral plate. Pigmented cartilage became impacted on less highly mineralized trabeculae and embedded in the marrow space. Pigmented cartilage samples were much stiffer than nonpigmented or OA cartilage as revealed by a significant difference in Young's modulus. CONCLUSION: Using alkaptonuria cartilage specimens with a wide spectrum of pigmentation, we have characterized the progression of ochronosis. Intact cartilage appears to be resistant to pigmentation but becomes susceptible following focal changes in calcified cartilage. Ochronosis spreads throughout the cartilage, altering the mechanical properties. In advanced ochronosis, there is aggressive resorption of the underlying calcified cartilage leading to an extraordinary phenotype in which there is complete loss of the subchondral plate. These findings should contribute to better understanding of cartilage-subchondral interactions in arthropathies.
Subject(s)
Alkaptonuria/complications , Bone and Bones/physiopathology , Calcinosis/physiopathology , Cartilage, Articular/physiopathology , Disease Progression , Ochronosis/etiology , Alkaptonuria/metabolism , Alkaptonuria/physiopathology , Bone and Bones/metabolism , Bone and Bones/pathology , Calcinosis/etiology , Calcinosis/pathology , Cartilage, Articular/metabolism , Cartilage, Articular/pathology , Extracellular Matrix/metabolism , Extracellular Matrix/pathology , Extracellular Matrix/ultrastructure , Hip Joint/pathology , Homogentisic Acid/metabolism , Humans , Knee Joint/pathology , Microscopy, Electron, Scanning , Microscopy, Fluorescence , Ochronosis/metabolism , Ochronosis/physiopathology , Osteoarthritis/metabolism , Osteoarthritis/pathology , Osteoarthritis/physiopathology , Pigmentation/physiologyABSTRACT
OBJECTIVES: Alkaptonuria (AKU) is an orphan disease that has an estimated prevalence of 0.3/100,000. The disease is caused by the lack of activity of homogentisic acid oxidase (HGO), an enzyme involved in tyrosine and phenylalanine metabolism. To date, there is only one drug, the nitisinone, with orphan designation authorised by both Food and Drug Administration (FDA) and European Medical Agency (EMA) for AKU. A clinical trial on AKU patients using nitisinone has recently been completed but it needs further investigation for long-term therapy. In recent years our group has developed a series of AKU in vitro models using cell lines, primary chondrocytes and human plasma in order to test the efficacy of new substances, mainly antioxidant compounds, for AKU therapy. Herein, we report the optimisation of an ex vivo reproducible culture method exploiting cartilage slices in order to investigate the deposition of ochronotic pigment in this kind of connective tissue. METHODS: Human normal cartilage slices, obtained after surgery for prosthesis replacement, were cultured for several days in the presence of a sublethal concentration of homogentisic acid (HGA). RESULTS: After two months of incubation with HGA, the peculiar melanin-like ochronotic pigmentation can be observed into the cartilage tissue. CONCLUSIONS: This novel organo-typic ex vivo model could be extremely useful to investigate the efficacy of substances able to ameliorate the conditions of AKU patients. Moreover, it could be used for genetic and proteomic investigations to better define AKU pathophysiology.